Got $1,000? Buy These 4 Cancer Stocks
Cancer therapeutics have come a long way in the last 10 years, with the rise of cancer immunotherapy and gene therapy providing ever-improving outcomes for patients. Investors keen on profiting from these ongoing and future advances in biomedical science will need to round out their portfolio with the right oncology companies.
I've identified four promising oncology companies based on their innovative drug development activities as well as their potential for growth in the next five years. Read on to see why these companies are noteworthy, how their approach measures up to the competition, and when you should consider investing to capture the greatest returns.
Source Fool.com
